Evidence map›Paper›PMID 28035321›Full record

ArticleBladder cancer (Amsterdam, Netherlands)2016

Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.

Tracy L Rose, Allison M Deal, Sylvain Ladoire, Gilles Créhange, Matthew D Galsky, Jonathan E Rosenberg, Joaquim Bellmunt, Akhila Wimalasingham, Yu-Ning Wong, Lauren C Harshman and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in Bladder cancer (Amsterdam, Netherlands), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 5 countries.

Tracy L RoseLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC, USA.
Allison M DealLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC, USA.
Sylvain LadoireGeorges François Leclerc Center, University of Burgundy , Dijon, France.
Gilles CréhangeGeorges François Leclerc Center, University of Burgundy , Dijon, France.
Matthew D GalskyIcahn School of Medicine at Mount Sinai , New York, NY, USA.
Jonathan E RosenbergMemorial Sloan Kettering Cancer Center , New York, NY, USA.
Joaquim BellmuntLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute , Harvard Medical School, Boston, MA, USA.
Akhila WimalasinghamBarts Cancer Institute ECMC, Barts Health and the Royal Free NHS Trust, Queen Mary University of London , London, UK.
Yu-Ning WongFox Chase Cancer Center, Temple University Health System , Philadelphia, PA, USA.
Lauren C HarshmanLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute , Harvard Medical School, Boston, MA, USA.
Simon ChowdhuryGuy's and St. Thomas' Hospital , London, UK.
Guenter NiegischDepartment of Urology, Medical Faculty, Heinrich-Heine-University , Düsseldorf, Germany.
Michalis LiontosUniversity of Athens , Athens, Greece.
Evan Y YuFred Hutchinson Cancer Research Center , Seattle, WA, USA.
Sumanta K PalCity of Hope Comprehensive Cancer Center , Duarte, CA, USA.
Ronald C ChenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC, USA.
Andrew Z WangLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC, USA.
Matthew E NielsenLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC, USA.
Angela B SmithLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC, USA.
Matthew I MilowskyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC, USA.
Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators
University of North Carolina at Chapel Hill · USFox Chase Cancer Center · USMemorial Sloan Kettering Cancer Center · USNational and Kapodistrian University of Athens · GRSt Thomas' Hospital · GBUniversité de Bourgogne · FRFred Hutch Cancer Center · USHarvard University · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
Translational Nanosystems for Improved Lung Cancer Treatment with Small MoleculesU54CA151652 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESIMONE, JOSEPH M. · 2010 to 2014
$12.1M
UNC Oncology K12K12CA120780 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WILLIAM Y. KIM · 2007 to 2026
$9.6M
UNC Clinical Translation Science Award-K12 Scholars Program (KL2)KL2TR000084 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUNGE, MARSCHALL S. · 2012 to 2013
$2.3M
Nanoparticle formulations of DNA repair inhibitors to improve chemoradiotherapyR01CA178748 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WANG, ANDREW ZHUANG · 2013 to 2017
$1.6M
NCATS NIH HHS KL2 TR000084NCI NIH HHS K12 CA120780NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA178748NCI NIH HHS U54 CA151652
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chemoradiotherapycomparative effectiveness researchcystectomyTransitional cell carcinoma

Identifiers

PMID28035321
PMCPMC5181658
OpenAlexW2532767791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.